Product Name: FTL1 Antibody [FTL/1386]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC, WB
Applications: Western blot: 0.1-0.2 ug/mlFlow Cytometry: 0.1-0.2ug/10^6 cellsIF: 0.1-0.2 ug/mlIHC (FFPE): 0.1-0.2 ug/ml for 30 min at RTThe concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Ferritin Light Chain antibody to be titered up or down for optimal performance.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Amino acids 38-165 of human FTL were used as the immunogen for this Ferritin Light Chain antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1078166-57-0
product targets : PTEN inhibitors
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: FTL, MGC71996, LFTD, NBIA3
Accession NO.:
Protein Ino:
Official Symbol: FTL
Geneid: 2512
Background: Mammalian ferritins consist of 24 subunits made up of 2 types of polypeptide chains, ferritin heavy chain and ferritin light chain. Ferritin heavy chains catalyze the first step in iron storage, the oxidation of Fe (II), whereas ferritin light chains promote the nucleation of ferrihydrite, enabling storage of Fe (III). Light chain ferritin is involved in cataracts by at least two mechanisms, hereditary hyperferritinemia cataract syndrome, in which light chain ferritin is overexpressed, and oxidative stress, an important factor in the development of ageing-related cataracts.
PubMed ID:http://aac.asm.org/content/41/8/1808.abstract
